My research at Yale University is dedicated to advancing our understanding and treatment of gastroesophageal cancer (GEC). GEC poses a significant challenge due to its complex nature and poor prognosis, especially when accompanied by peritoneal metastases. I am passionate about uncovering the intricacies of the tumor microenvironment and the mechanisms of metastasis through cutting-edge multiomic and spatial profiling techniques. My ultimate goal is to translate these discoveries into personalized therapeutic strategies that significantly improve patient outcomes.

My current work is centered on exploring the complexities of the tumor microenvironment in gastroesophageal cancer (GEC). By leveraging advanced technologies such as spatial profiling, my research investigates the genomic and transcriptomic alterations driving GEC and its metastases. I aim to identify biomarkers and therapeutic vulnerabilities within the GEC landscape, leading to the development of novel treatment strategies. Additionally, my role as Principal Investigator in clinical trials highlights the translational aspect of my research, where I strive to bring laboratory discoveries into clinical practice.

I am particularly proud of several key achievements in my research career. Our study published in Cancer Discovery revealed novel tumor ecosystem states and critical genetic drivers, providing insights into gastric adenocarcinoma progression. Another notable accomplishment was our work in Gastroenterology, where we provided comprehensive molecular characterization of peritoneal metastases, uncovering unique therapeutic targets. Additionally, leading clinical trials such as the Phase I PIANO trial, which combined PIPAC-OX and nivolumab, demonstrated the potential efficacy of integrating locoregional and systemic therapies. These achievements not only advance the scientific community's understanding of gastroesophageal cancer but also pave the way for improved patient outcomes.